Homepage>Company>Media>Pharma News>2019>Clovis Oncology, Inc. is discontinuing its sponsored Phase 2 open-label monotherapy clinical trial evaluating rucaparib in recurrent, metastatic bladder cancer
Clovis Oncology, Inc. is discontinuing its sponsored Phase 2 open-label monotherapy clinical trial evaluating rucaparib in recurrent, metastatic bladder cancer